Astrazeneca Ab

Cancer Research Technology Limited

Piotr Antoni Raubo

Richard Evans

Maurice Raymond Verschoyle Finlay

Johannes Wilhelmus Maria Nissink

Timothy Jon Luker

Stephen Brough

Mark David Charles

Chukuemeka Tennyson Ekwuru

Jonathan James Gordon Winter

Maurice Raymond Finlay

Roger Victor Bonnert

Stephen Connolly

Paul Andrew Willis

Bryan Glyn Roberts

Anthony Ronald Cook

Andrew Bailey

Barrie Martin

Stephen Anthony St-Gallay

Peter Duncan Smith

Matthew Hallam

David Robert Perkins

Jonathan James Winter

Johannes Wilhelmus Nissink

Stephen St-Gallay

Paul Willis

The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Q, R, Rand Rhave any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts.

1, 3, 4-thiadiazole compounds and their use in treating cancer

The specification relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where Q, R, Rand Rhave any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts. 

1,3,4-thiadiazole compounds and their use in treating cancer

The present invention relates to pyrazinone derivatives of formula (I): wherein R, R, R, R, R, Rand Rare as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses

N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses

Compounds and their uses 708

The present invention provides a compound of formula (I) wherein W, R, Rand Rare as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

N-(2-(2-(5-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)ethylamino)ethyl)-3-(phenethoxy)propanamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy

The present invention relates to isoquinolinone derivatives of formula (I): wherein R, R, R, R, R, Rand Rare as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Compounds and their uses 707

Growing community of inventors

Cambridge, United Kingdom

Piotr Antoni Raubo